BiotechFeatured

NanoViricides: A Unicorn For Biotech Investors

The OTC markets are crammed with zero-revenue biotech firms on the lookout for analysis funding by way of issuance of fairness however it’s often very troublesome for traders to judge the longer term potential of most of those gamers given the complexity of their analysis, the uncertainty related to their product launches and revenues, and the truth that these firms haven’t any actual monetary fundamentals. Given this example, the most effective metrics for analysis utilized by all biotech traders are the standing of the drug pipeline, the time-to-commercialization, and measurement of the addressable markets. Few firms come up as true potential winners with a number of medication at superior levels of trials, a brief time-to-market, and a big addressable buyer base and NanoViricides (NYSE-Amer.:NNVC) is unquestionably one of many top-most firms inside this shortlist.

What Does NanoViricides Do?

Founded in 2005, NanoViricides, Inc. is a improvement stage nano-biopharmaceutical firm with its analysis targeted on countering viral infections. Its analysis entails using a singular nanomedicine know-how referred to as nanoviricides – brokers designed to “fool” a virus into attaching to an antiviral nanomachine, in the identical approach that the virus usually attaches to the receptors on a cell floor, however for the aim of its neutralization and destruction. Based in Connecticut, the corporate is creating nanoviricide drug candidates in opposition to a number of commercially essential viral ailments, viz. chilly sores and genital herpes an infection, shingles rash, viral eye ailments, seasonal and potentially-epidemic influenzas and fowl flu, HIV/AIDS, in addition to dengue viruses.

Solid Manufacturing Capability

What makes NanoViricides distinctive is the truth that the corporate has its personal cGMP manufacturing functionality for its complicated nanomedicine medication. This has enabled the administration to optimize manufacturing time to a security/tox examine high quality drug product and to reduce the associated prices. They haves the capability to fabricate its drug candidates as wanted for human medical trials at this facility, permitting speedy progress to medical trials. In reality, when it comes to the manufacture of polymers for the merchandise, the crew has manufacturing management to the extent of 1 monomer unit with respect to their size which is an immense achievement for a corporation that’s nonetheless within the improvement section. This one-of-a-kind manufacturing functionality is the primary massive inexperienced flag in favor of the stock. It can be value mentioning that the corporate is working with no debt and has 10.2Million of mounted belongings, not counting the worth of their state-of-the-art lab gear. 

NV-HHV-101 – NanoViricides’s Lead Drug Candidate

NanoViricides’ lead drug candidate is NV-HHV-101, formulated as a pores and skin cream for topical therapy of shingles rash attributable to VZV. It is on monitor with required preclinical GLP Safety and Toxicology research transferring in direction of human medical trials. The administration has acknowledged that NV-HHV-101 has been discovered to be secure within the medical remark of the GLP Safety/Toxicology examine of the drug as a dermal therapy for shingles.

The first of the GLP research following dermal therapy, was performed utilizing minipigs, who obtained twice daily pores and skin therapy for 28 days, at completely different dosage ranges. The animals have been evaluated daily for normal indicators of toxicity and particular analysis of the pores and skin therapy areas. The research have been successful because the topical therapy of the pores and skin in any respect doses was properly tolerated in all animals and all measured parameters remained inside regular vary within the examine. The administration has beforehand discovered that NV-HHV-101 was secure and properly tolerated in non-GLP security/toxicology research. 

The firm anticipates advancing NV-HHV-101 into human medical trials because the preliminary indication and in addition evaluating different variations of the identical candidate, for the therapy of different herpes viruses, particularly HSV-1 chilly sores and HSV-2 genital herpes. These are anticipated to comply with the shingles candidate into IND-enabling improvement after which into human medical trials. The estimated market measurement of this HerpeCide program (HSV-1 and HSV-2) is variously estimated to be over 10 billion {dollars}.

President and Executive Chairman Anil Diwan believes that the dermal topical cream for the therapy of shingles rash would be the first drug heading into medical trials which once more caters to a market over 1 billion {dollars}. There is at the very least 1 extra 12 months till commercialization and for revenues to move into the corporate. However, it’s clear that with such a big addressable market measurement and hardly any competitors, the success of the human trials would consequence within the stock value leaping.

NanoViricides’s Other Current Pipeline

Nanoviricides is creating anti-influenza drug candidates at pre-clinical and superior pre-clinical stage, which embody two FluCide medication, similar to injectable and oral anti-influenza nanoviricide drug for H7N9. The injectable answer is supposed for hospitalized sufferers whereas the oral answer is for out-patients. These are all within the IND-enabling research section.

The firm is creating drug candidates for Bird Flu H5N1, different extremely pathogenic influenzas, epidemic influenzas, and seasonal influenzas. DengueCide, its anti-dengue nanoviricide which is in pre-clinical improvement is present process animal testing whereas its HIVCide, an anti-human immunodeficiency virus drug candidate, can be nearing the IND-enabling research section. The firm can be creating eye drops in opposition to viral infections of the exterior eye, and is concerned within the different analysis packages in opposition to Rabies virus, Ebola, and Marburg viruses. 

Current Value & Key Takeaways

The present market capitalization of NanoViricides is about $16 million and the most important part inside this worth is the value of its manufacturing facility which is near $10 million. It is clear that the corporate’s stock is buying and selling at a heavy low cost because the market is unable to issue for the wonderful potential of its merchandise, significantly its cream options catering to shingles that are little over a 12 months away from commercialization plus its herpes candidates which aren’t too far behind both. Given these elements, the promising pipeline, and a big addressable market measurement, it’s evident that the stock has a superb upside potential within the long-term. The first soar within the value is predicted when the corporate’s topical cream for shingles enters human trials. That occasion will validate that the nanoviricides® platform know-how is able to delivering medication into the regulatory pipeline. Biotech traders should soar on this stock whereas it’s low cost as a result of it’s definitely a matter of time earlier than the market realizes its true potential.


DISCLAIMER

SmallCapsDaily has not been compensated in any approach for this text. This article shouldn’t be thought of or used as funding recommendation.

Show More

Related Articles

Back to top button
Close